Anti-Human C79a PerCP-Cyanine5.5

Grouped product items
Size Price Qty
100 tests
$365.00

Additional HM47 Formats

Cat.No. Format Starting From
09511-70 PerCP-Cyanine5.5 $ 365.00
09511-60 PE $ 145.00
09511-80 APC $ 165.00
Catalog Number : 09511-70

description

The HM47 monoclonal antibody reacts with the cytoplasmic domain of CD79a, a 47kDa type I integral membrane protein known as Iga or mb-1. It forms the part of the B-cell receptor complex with CD79b and is expressed on B cells from earliest pre-B to plasma cell stage. It is also reported that CD79a expresses weakly on myeloid cells and T cell precursors. CD79a is believed to be involved in transporting IgM to the surface of B cells.

Additional Information

Clone:
HM47
Format:
PerCP-Cyanine5.5
Applications:
FC
Reactivity:
Human, Mouse
Isotype:
Mouse IgG1, kappa
Research Interest: Adaptive Immunity
Cell Type: B Cells
Application: FC
Clone: HM47
Preparation:
The product should be stored undiluted at 4°C and should be protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified utilizing affinity chromatography and unreacted dye was removed from the product.
Formulation:
Phosphate-buffered aqueous solution, ≤0.09% Sodium azide, may contain carrier protein/stabilizer, ph7.2.
References:

Mason, D. Y., Cordell, J. L., Tse, A. G., Van Dongen, J. J., Van Noesel, C. J., Micklem, K., ... & Borst, J. (1991). The IgM-associated protein mb-1 as a marker of normal and neoplastic B cells. Journal of immunology (Baltimore, Md.: 1950)147(11), 2474-2482.

Bhargava, P., Kallakury, B. V., Ross, J. S., Azumi, N., & Bagg, A. (2007). CD79a is heterogeneously expressed in neoplastic and normal myeloid precursors and megakaryocytes in an antibody clone–dependent manner.American journal of clinical pathology128(2), 306-313.

Hashimoto, M., Yamashita, Y., & Mori, N. (2002). Immunohistochemical detection of CD79a expression in precursor T cell lymphoblastic lymphoma/leukaemias. The Journal of pathology197(3), 341-347.

© BioGems International, Inc. All rights reserved.